NASDAQ · VTRS
Healthcare · Drug Manufacturers - Specialty & Generic
$17.62
Up+$0.02 (+0.11%)
Updated Oct 6, 2026, 5:46 AM
SID Score
7.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · VTRS
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
VTRS closed at $17.62 after 20 trading sessions, up 6.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $17.82 | $17.91 | $17.45 | $17.62 | 6.36M |
| Oct 2, 2026 | $17.53 | $17.65 | $17.34 | $17.60 | 7.53M |
| Oct 1, 2026 | $17.62 | $17.835 | $17.43 | $17.46 | 9.04M |
| Sep 30, 2026 | $18.16 | $18.17 | $17.71 | $17.72 | 11.81M |
| Sep 29, 2026 | $18.25 | $18.43 | $17.865 | $18.12 | 13.86M |
| Sep 28, 2026 | $17.75 | $18.37 | $17.5406 | $18.27 | 12.38M |
| Sep 25, 2026 | $17.52 | $17.975 | $17.37 | $17.83 | 10.15M |
| Sep 24, 2026 | $17.05 | $17.45 | $17.00 | $17.42 | 13.74M |
| Sep 23, 2026 | $17.255 | $17.595 | $16.99 | $17.12 | 6.87M |
| Sep 22, 2026 | $17.10 | $17.23 | $16.98 | $17.18 | 5.24M |
| Sep 21, 2026 | $16.98 | $17.35 | $16.865 | $17.10 | 6.94M |
| Sep 18, 2026 | $17.19 | $17.20 | $16.91 | $16.95 | 15.65M |
| Sep 17, 2026 | $17.10 | $17.305 | $17.09 | $17.13 | 7.02M |
| Sep 16, 2026 | $16.75 | $17.05 | $16.665 | $17.02 | 8.64M |
| Sep 15, 2026 | $16.63 | $16.67 | $16.38 | $16.65 | 6.84M |
| Sep 14, 2026 | $16.64 | $16.8466 | $16.47 | $16.66 | 7.03M |
| Sep 11, 2026 | $16.50 | $16.65 | $16.32 | $16.51 | 12.17M |
| Sep 10, 2026 | $16.50 | $16.51 | $16.15 | $16.38 | 9.01M |
| Sep 9, 2026 | $16.72 | $16.84 | $16.40 | $16.50 | 6.51M |
| Sep 8, 2026 | $16.63 | $16.765 | $16.4201 | $16.61 | 4.39M |
The latest Smart Investors Daily articles mentioning VTRS.
Company
Market Activity
Research & News
VTRS research
Company profile and research snapshot.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Outperform | — |
| Sep 16, 2026 | Piper Sandler | Neutral | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 8, 2026 | Argus Research | Buy | — |
| May 19, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
SeekingAlpha · Sep 30, 2026
Aquestive Therapeutics offers a differentiated epinephrine product, Anaphylm, but faces pricing and market share headwinds. Learn why AQST stock is a hold.
Yahoo · Sep 29, 2026
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth consecutive year. The ranking is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider, and is based on independent employee feedback collected globally, highlighting employee trust, workplace experience and organizational culture at Viatris.
ChartMill · Sep 28, 2026
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.
Yahoo · Sep 25, 2026
Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company's patent rights.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VTRS.
